PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC Feb 21, 2007.
Published in final edited form as:
PMCID: PMC1802660
NIHMSID: NIHMS17735
A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma
Deyin Xing1,2 and Sandra Orsulic1,2
1 Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts
2 Department of Pathology, Harvard Medical School, Boston, Massachusetts
Requests for reprints: Sandra Orsulic, Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, 13th Street, Building 149, CNY7, Charlestown, MA 02129. Phone: 617-726-5674; Fax: 617-726-5684; E-mail: sorsulic/at/partners.org.
Little is known about the mechanisms that underlie Brca1-associated ovarian tumorigenesis, mainly due to the lack of an appropriate experimental model. We developed genetically defined primary mouse ovarian surface epithelial (OSE) cell lines in which the loss of functional Brca1 and p53 recapitulates the events that are thought to occur in early ovarian cancer development in patients with Brca1 mutations. This system allows for the introduction of additional oncogenes that are thought to cooperate with the loss of Brca1 and p53 to induce tumorigenesis. We showed that Myc is sufficient to induce transformation of ovarian cells that are deficient for both Brca1 and p53 but not sufficient for the transformation of cells that are deficient for either Brca1 or p53. The transformed Brca1-deficient OSE cells display an increased number of centrosomes, acquire complex chromosome aberrations, and lack Rad51 nuclear foci in the presence of DNA-damaging agents, such as mitomycin C and cisplatin. Immunocompetent mice injected with transformed OSE cells develop tumors that resemble human metastatic serous ovarian carcinoma, the most common type of ovarian cancer in women. Consistent with the reported platinum chemo-sensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells. The Brca1 wild-type and Brca1-deficient mouse ovarian tumors and cell lines provide a new experimental system for the evaluation of therapies that target the Brca1 pathway.
The majority of hereditary ovarian cancers are of a serous type and can be attributed to germ-line mutations in the Brca1 tumor suppressor gene. Hereditary and sporadic ovarian cancers are similar in many respects; however, patients with hereditary mutations in Brca1 develop ovarian cancers earlier than patients with sporadic cancers (1), suggesting that the loss of the Brca1 function lowers the threshold for oncogenic transformation. The loss of heterozygosity for Brca1 and the inactivation of the p53 function seem to be the early events in the induction of hereditary ovarian cancer (2). Consistent with this, familial ovarian cancers have a significantly higher frequency of p53 mutations than sporadic cancers (3), indicating that the loss of p53 function is required for a cell to tolerate the loss of the Brca1 function (4). However, little is known about the requirement for additional genetic alterations that collaborate with Brca1 and p53 in the transformation of ovarian surface epithelial (OSE) cells. Considering the distinct clinical, histopathologic, and molecular aspects of Brca1-associated ovarian cancers, there is a great need to generate ovarian cancer mouse models for the comparison of Brca1 wild-type and Brca1-deficient ovarian tumors.
Mouse strains
K5-TVA mice (5) were crossed with Brca1lox/lox (6), p53lox/lox (7), or p53−/− (8) mice. Triple transgenic K5-TVA; Brca1lox/lox; p53lox/lox mice were generated by crossing K5-TVA; Brca1lox/lox and K5-TVA; p53lox/lox mice.
Retroviral constructs and generation of genetically defined ovarian cancer cell lines
Replication-competent avian leukosis virus long terminal repeat with splice acceptor (RCAS) retroviral constructs and viral infection of mouse ovarian explants have been described (5, 9). For the generation of C1, C11, C2, C22, and C3 cell lines, ovarian explants from K5-TVA; p53−/− mice (5) were infected with different combinations of RCAS viruses carrying human Myc, mouse K-rasG12D, and mouse myristoylated Akt1 oncogenes: C1 and C11 (Myc plus K-ras), C2 and C22 (Akt plus Myc), and C3 (Akt plus K-ras). The BR2, BR5, and BR6 cell lines were derived by RCAS-Cre and RCAS-Myc infection of ovarian explants from mice with K5-TVA; Brca1lox/lox; p53lox/lox genetic background. Tumors from nude mice injected with the Brca1 wild-type cell lines C1, C11, C2, C22, and C3 were used to generate T1, T11, T2, T22, and T3 tumor cell lines, whereas tumors from nude mice injected with the Brca1-deficient cell lines BR2, BR5, and BR6 were used to generate the TBR2, TBR5, and TBR6 tumor cell lines.
Confirmation of gene recombination and expression
Genomic DNA extracted from different cell lines was used to detect the Cre-mediated recombination of the p53 and Brca1 genes. The primers used for the PCR and reverse transcription-PCR (RT-PCR) analyses are described in Supplementary Materials and Methods.
Tumor production and immunodetection of proteins
Tumor production, Western blotting, immunohistochemistry, and immunofluores-cence were done as described previously (9) The antibodies used for immunodetection of proteins are described in Supplementary Materials and Methods.
Cell treatment with mitomycin C, cisplatin, and paclitaxel
Equal numbers of cells were plated into six-well dishes in DMEM/F12 with 10% FCS. After 1 day of growth in culture, the medium was replaced with a medium that contained 1μg/mL mitomycin C (MMC; Roche, Indianapolis, IN) or gradually increasing concentrations of cisplatin (cis-diamminedi-chloroplatinum, Calbiochem, Darmstadt, Germany) or paclitaxel (Baccatin III N-benzyl-β-phenylisoserine ester, LC Laboratories, Woburn, MA). The cells were treated with MMC overnight or with cisplatin or paclitaxel for 8 days. Cell numbers were determined using a counting chamber (Hausser Scientific, Horsham, PA). To determine chromosome breakage, subconfluent cells were exposed to 1 μmol/L cisplatin for 48 hours and metaphase chromosomes were prepared as described previously by Litman et al. (10).
Myc cooperates with the loss of Brca1 and p53 in transforming mouse OSE cells
We have developed a K5-TVA-RCAS system in which defined multiple genetic alterations can be introduced into mouse OSE cells (5, 9), a single layer of cells that is believed to be the precursor for ovarian carcinoma. We have previously shown that the minimal requirement for the transformation of OSE cells from p53-deficient mice is a combination of any two of the following oncogenes: Myc, K-ras, and Akt (5). To identify the minimal requirement for the transformation of mouse OSE cells that are deficient for both Brca1 and p53, we crossed K5-TVA (5), Brca1lox/lox (6), and p53lox/lox (7) transgenic mice. The triple transgenic system allows for conditional inactivation of Brca1 and p53 in OSE cells as well as the introduction of putative oncogenes that are thought to collaborate with Brca1 and p53 in tumorigenesis. Ovarian explants isolated from K5-TVA; Brca1lox/lox; p53lox/lox transgenic mice were infected in vitro with RCAS-Cre along with RCAS vectors carrying K-ras, HER-2, Akt, or Myc genes. We determined that the Myc oncogene is capable of transforming cells that are deficient for both Brca1 and p53, whereas K-ras, HER-2, and Akt are not sufficient for the transformation of these cells (Table 1). Myc, however, is not sufficient for the transformation of ovarian cells with intact Brca1 or p53 (Table 1).
Table 1
Table 1
Identification of oncogenes that cooperate with the loss of p53 and/or Brca1 in inducing transformation of mouse OSE cells
The mechanism by which Myc transforms Brca1- and p53-deficient mouse OSE cells is presently unknown. Tumor growth requires the activation of proliferative signals and amplification of the Myc gene might be sufficient to provide these signals. However, other oncogenes, such as activated Akt, K-ras, and HER-2, which are known to induce strong proliferative signals, were not sufficient for the transformation of the Brca1- and p53-deficient OSE cells in our assay. This suggests that Myc may play a different and possibly more direct role in the transformation of mouse OSE cells that are deficient for Brca1 and p53. Brca1 physically associates with Myc and represses its transcriptional and transformative activity (11). It has also been shown in transgenic mice that deregulated Myc expression leads to DNA damage and genomic instability, which induces p53 activation and apoptosis (12). However, in the absence of the p53 function, rather than leading to apoptosis, Myc-induced DNA damage may lead to uncontrolled genomic instability and cell proliferation. The amplification of Myc and the loss of the p53 function often accompany the Brca1 mutation in human and mouse breast tumors (13, 14), providing additional support for the role of Myc and p53 in Brca1-associated tumor progression. Use of high-throughput technology, such as microarray analysis and comparison of OSE cell lines with different genetic alterations, might shed light on the cooperative pathways among Myc, p53, and Brca1.
Serous ovarian carcinomas develop in mice injected with Brca1 wild-type and Brca1-deficient mouse OSE cells
Three independent OSE cell lines, designated as BR2, BR5, and BR6, were generated by infection of the ovaries from K5-TVA; Brca1lox/lox; p53lox/lox mice with a combination of RCAS-Cre and RCAS-Myc. PCR of mouse tail DNA and the corresponding transformed OSE cell line DNA was used to confirm the deletion of exons 2 to 10 in p53 and exon 11 in Brca1 in the transformed OSE cell lines (Fig. 1A). Because both p53 and Brca1 are located on chromosome 11, Cre-loxP-mediated recombination may result in recombination between p53 and Brca1 loci, potentially influencing carcinogenesis. PCR with four combinations of primers (Fig. 1) flanking p53 (Fig. 1A, a and c) and Brca1 (Fig. 1A, d and g) loxP sites did not detect such alterations (data not shown). OSE cell lines that are wild-type for Brca1 were generated by the infection of ovarian explants from K5-TVA; p53−/− mice with combinations of RCAS vectors carrying Myc, K-ras, and Akt oncogenes as described previously (5, 9). RT-PCR (Fig. 1B) was used to detect the presence of p53, Brca1, Myc, and β-actin in mouse embryonic fibroblasts (MEFs), mouse ovarian cancer cell lines deficient for p53 and wild-type for Brca1 (C1, C2, and C3), and mouse ovarian cancer cell lines deficient for both Brca1 and p53 (BR2, BR5, and BR6). A Western blot of whole-cell extracts from Brca1 wild-type and Brca1-deficient (exon 11 deleted) cell lines with a Brca1 antibody shows expression of the 210-kDa wild-type Brca1 and the 92-kDa Brca1Δ11 spliced product (Fig. 1C). Brca1 is known to play a role in the fidelity of centrosome duplication (15) and localization of DNA repair proteins, such as Rad51, to the DNA damage-induced foci (16). Consistent with the requirement for Brca1 in these processes, Brca1-deficient cell lines displayed an increased number of centrosomes (Supplementary Fig. S1) and lacked Rad51 nuclear foci in the presence of the DNA cross-linking agent MMC (Fig. 1D).
Figure 1
Figure 1
Characterization of genetically defined mouse ovarian cancer cell lines. A, detection of deleted p53 (exons 2–10), conditional Brca1, deleted Brca1 (exon 11), and tva alleles by PCR using DNA from mouse tails (2, 5, 6) and the corresponding transformed (more ...)
I.p. injection of Brca1 wild-type and Brca1-deficient cell lines into nude or FVB mice invariably resulted in metastatic tumor formation. Similar to human ovarian tumors, the mouse tumors were associated with the accumulation of hemorrhagic ascites and bloating (Fig. 2A). The tumor nodules grew on the surfaces of organs without significant invasion. Tumor spread sites included the mesothelial lining of the peritoneum, intestines, pancreas, and diaphragm, whereas the liver, spleen, and kidneys were typically spared from tumor spread. Both Brca1 wild-type and Brca1-deficient tumors were characterized by papillary structures typical of serous papillary carcinoma (Fig. 2B), which is the most common type of hereditary ovarian cancer. The OSE cell origin of the tumors was confirmed by the presence of the epithelial cell marker keratin 8 (Fig. 2C). The cell lines that were derived from the transformed primary ovarian epithelial cells and the mouse tumors maintained the typical epithelial cobblestone morphology of OSE cells (Supplementary Fig. S2).
Figure 2
Figure 2
Phenotypic properties of transformed ovarian cells and tumors that are wild-type or deficient for Brca1. A, ascites accumulation and carcinomatosis are apparent 4 to 10 weeks after i.p. injection of the Brca1 wild-type C2 cells (n = 10) and 10 to 14 weeks (more ...)
Loss of Brca1 function increases sensitivity of mouse OSE cells to the DNA-damaging agent cisplatin
Administration of the microtubule poison paclitaxel and the DNA-damaging agent cisplatin is a current standard of postoperative chemotherapy for patients with advanced ovarian cancer. Patients with hereditary ovarian cancers display a longer recurrence-free interval following chemotherapy and have a longer overall survival rate (1). This phenomenon is likely due to induced chromosomal instability, cell cycle arrest, and subsequent apoptosis in cells that lack Brca1 and thus cannot repair the induced DNA damage. To test whether Brca1 status influences the sensitivity of OSE cells to drugs with different mechanisms of action, we compared the sensitivity of Brca1 wild-type and Brca1-deficient OSE cells to paclitaxel and cisplatin. OSE cell lines that are wild-type (C1, C2, C3, T1, T2, and T3) or deficient for Brca1 (BR2, BR5, BR6, TBR2, TBR5, and TBR6) were tested for their rate of survival in increasing concentrations of paclitaxel and cisplatin at doses that are effective in human ovarian cancer cell lines that harbor defined genetic alterations in genes such as Brca2, p53, K-ras, TGFβ-RII, and CDNK2A (17). We showed that transformed Brca1 wild-type and Brca1-deficient mouse OSE cell lines have a similar sensitivity to the microtubule poison paclitaxel (Fig. 3A). However, the DNA-damaging agent cisplatin was significantly more effective in inducing cell death in the Brca1-deficient cell lines (Fig. 3A), presumably because these cells are unable to repair cisplatin-induced DNA damage. The exposure of ovarian cancer cell lines lacking functional Brca1 to 1 μmol/L cisplatin for 48 hours resulted in chromatid breaks and other complex chromatid aberrations, such as triradial and quadriradial chromosomes (Fig. 3B). We hypothesized that, in this case, Brca1 functioned as a chemotherapy sensitivity modulator independent of oncogenic composition. Consistent with this hypothesis, we showed that the introduction of Akt or H-ras into the Brca1-deficient TBR5 cell line results in a similar response to cisplatin or paclitaxel compared with that of TBR5 cells with an empty vector (Supplementary Fig. S3). Similarly, it has been shown that the K-ras status in human ovarian cancer cell lines does not affect chemosensitivity to paclitaxel and cisplatin (17, 18).
Figure 3
Figure 3
Sensitivity of Brca1 wild-type and Brca1-deficient cells to drugs with differential mechanisms of action. A, sensitivity of Brca1 wild-type (C1, C2, C3, T1, T2, and T3) and Brca1-deficient (BR2, BR5, BR6, TBR2, TBR5, and TBR6) cell lines to the microtubule (more ...)
Although these studies were done in culture, our results concur with previous findings that Brca1-deficient human ovarian cancer cells have a greater sensitivity to cisplatin in vitro (16) and that patients with Brca1-associated ovarian carcinoma respond better to platinum-based therapies (1, 19). The increased sensitivity of the Brca1-deficient OSE cells to cisplatin and the reported platinum chemosensitivity displayed by patients with Brca1-associated ovarian cancer raise the question about whether platinum agents would be effective in the treatment of patients with Brca1-associated breast cancer. This biochemical difference between Brca1 wild-type and Brca1-deficient cells provides an opportunity to develop novel therapeutic agents that generate specific DNA lesions that require functional Brca1 for their repair. The compelling factor of this type of therapy is its selectivity; the nontumor cells that are heterozygous for Brca1 should have normal Brca1 function and, therefore, normal levels of DNA repair, whereas the Brca1-deficient tumor cells should be highly sensitive to DNA-damaging treatments (20). Unlike cell lines isolated from human tumors, the Brca1 wild-type and Brca1-deficient mouse OSE cell lines are capable of forming serous papillary carcinomas in immunocompetent mice, thus providing a unique experimental model to study the sensitivity of ovarian tumors to various therapies that may interfere with the immune system. We anticipate that this mouse model will facilitate the evaluation of various therapies that target the Brca1 pathway as well as assist in the identification of novel biochemical pathways that are associated with hereditary ovarian cancers.
Supplementary Material
Supplementary Material and Methods and Supplementary Figures
Acknowledgments
Grant support: Department of Defense Ovarian Cancer Research Program Institutional Training grant and Ovarian Cancer Research Fund Program of Excellence grant MGH/POE01.06 (D. Xing) and NIH grants RO1CA103924 and UO1CA105492, Department of Defense grant W81XWH-04-1-0485, and Career Development Award under Ovarian Specialized Program of Research Excellence P50CA105009 (S. Orsulic).
We thank Mouse Models of Human Cancer Consortium Mouse Repository for the mouse strains, Esther Oliva for her pathology expertise, Shridar Ganesan for the Brca1 antibody, Michael Seiden and Daniel Haber for their critical reading of the article, and Kristy Daniels for assistance in the preparation of the article.
Footnotes
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
1. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187–95. [PubMed]
2. Werness BA, Parvatiyar P, Ramus SJ, et al. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst. 2000;92:1088–91. [PubMed]
3. Ramus SJ, Bobrow LG, Pharoah PD, et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer. 1999;25:91–6. [PubMed]
4. Schuyer M, Berns EM. Is TP53 dysfunction required for BRCA1-associated carcinogenesis? Mol Cell Endocrinol. 1999;155:143–52. [PubMed]
5. Orsulic S, Li Y, Soslow RA, et al. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 2002;1:53–62. [PMC free article] [PubMed]
6. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22:37–43. [PubMed]
7. Jonkers J, Meuwissen R, van der Gulden H, et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001;29:418–25. [PubMed]
8. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4:1–7. [PubMed]
9. Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A. 2005;102:6936–41. [PubMed]
10. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell. 2005;8:255–65. [PubMed]
11. Wang Q, Zhang H, Kajino K, Greene MI. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene. 1998;17:1939–48. [PubMed]
12. Pusapati RV, Rounbehler RJ, Hong S, et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci U S A. 2006;103:1446–51. [PubMed]
13. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004;10:499–507. [PubMed]
14. Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene. 2001;20:7514–23. [PubMed]
15. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell. 1999;3:389–95. [PubMed]
16. Zhou C, Huang P, Liu J. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem Biophys Res Commun. 2005;336:952–60. [PubMed]
17. Samouelian V, Maugard CM, Jolicoeur M, et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53, and/or CDNK2A. Cancer Chemother Pharmacol. 2004;54:497–504. [PubMed]
18. Holford J, Rogers P, Kelland LR. Ras mutation and platinum resistance in human ovarian carcinomas in vitro. Int J Cancer. 1998;77:94–100. [PubMed]
19. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659–68. [PubMed]
20. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005;5:388–93. [PubMed]